A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
复制标题
DOI：
10.1177/23247096211058489
复制
发表时间：
2021-01
影响因子：
1.2
通讯作者：
Moriyama M
中科院分区：
文献类型：
--
作者：
Watanabe Y;Ogawa M;Tamura Y;Suda S;Kaneko M;Kumagawa M;Hirayama M;Matsumoto N;Yamamoto T;Moriyama M
一位74岁的男性被诊断为肝细胞癌。肝脏肿瘤在经导管动脉化疗栓塞后显示完全缓解，但观察到肺、骨和淋巴结转移，因此开始atezolizumab联合贝伐珠单抗治疗。给药后，扫描显示肿瘤生长，但连续给予atezolizumab+贝伐单抗后，肿瘤最终缩小并显示部分缓解。肿瘤的短暂生长被认为是假进展。在此，我们报告一例atezolizumab联合贝伐单抗治疗肝细胞癌的假进展。
A 74-year-old man was diagnosed with hepatocellular carcinoma. The tumor in the liver showed a complete response after transcatheter arterial chemoembolization, but lung, bone, and lymph node metastases were observed, so treatment with atezolizumab plus bevacizumab was initiated. After administration, the scans showed tumor growth, but after continuous administration of atezolizumab plus bevacizumab, the tumors finally reduced in size and showed a partial response. The transient growth of the tumors was considered to be pseudoprogression. Herein, we report a case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
登录
查看更多内容
影响因子：
10.9
作者：
Nishino M
通讯作者：
Nishino M
影响因子：
5.3
作者：
Tanizaki, Junko;Hayashi, Hidetoshi;Nakagawa, Kazuhiko
通讯作者：
Nakagawa, Kazuhiko
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen